Inovio Pharmaceuticals (INO)
NASDAQ:INO
Want to see INO full AI Analyst Report?
INO Stock Chart & Stats
$1.19
-$0.22(-9.65%)
At close: 4:00 PM EST
$1.19
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.03 - $2.98
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.17M
Market Cap
$95.44M
Enterprise Value$52.63M
Total Cash (Recent Filing)$37.68M
Total Debt (Recent Filing)$8.70M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,273,240
10 Day Avg. Volume1,920,366
30 Day Avg. Volume3,166,184
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)33.86
Price to Sales (P/S)12485.24
P/FCF Ratio-9.18
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.48
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$4.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$8.90M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAcceptance of the BLA and a defined PDUFA date materially reduces regulatory timing uncertainty and concentrates a clear path to potential approval. This durability improves commercial planning, partner engagement, and resource allocation, making launch and reimbursement planning more actionable over months.
Clinical Efficacy And SafetyConsistent Phase I/II efficacy (large surgery reductions) and a favorable safety profile provide durable clinical differentiation versus incumbents. Such outcomes support a strong label, physician adoption, and payer conversations that underpin sustained commercial uptake beyond near‑term launch activities.
Platform Validation & PartnershipsExternal partner success (ApolloBio VGX‑3100 Phase 3) and collaborations (Akeso, Dana‑Farber) validate Inovio’s DNA platform, creating durable non‑dilutive value streams via milestones/royalties and lowering technology risk. Partnerships also accelerate development and broaden commercial pathways long term.
Bears Say
Cash Burn And RunwayOperating and free cash flow are negative with substantial quarterly burn and runway only into Q1 2027 (ex‑financings). This persistent cash consumption creates structural funding risk that can force dilutive raises, delay programs, or limit commercial readiness if additional capital is not secured on acceptable terms.
Balance-sheet DeteriorationThe shift to debt exceeding equity and negative returns on equity marks a material loss of financial flexibility versus prior years. Higher leverage increases refinancing and covenant risk, constrains strategic choices, and raises the likelihood of dilutive or restrictive financing that could impede long‑term execution.
Competitive First‑moverA revenue‑generating competitor establishes first‑mover adoption and real‑world uptake, making Inovio a fast follower. This structural dynamic can depress initial penetration, require higher commercial spend, and limit pricing leverage, reducing sustainable market share and lengthening time to meaningful revenues.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.03 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $95.44M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.07.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 82,273,240 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (257.14% Upside)
$4.25 (257.14% Upside)
Blogger Sentiment
Bullish
INO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.52%
12-Months-Change
Fundamentals
Return on Equity
-666.47%
Trailing 12-Months
Asset Growth
-42.96%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
INO Company Deck
INO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$4.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
16.50% Mutual Funds
8.78% Other Institutional Investors
70.53% Public Companies and
Individual Investors